Last update 08 May 2025

Celecoxib

Overview

Basic Info

SummaryCELEBREX (celecoxib) is a nonsteroidal anti-inflammatory drug. Celecoxib has analgesic, anti-inflammatory, and antipyretic properties.The mechanism of action of CELEBREX is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of COX-2. Celecoxib is a potent inhibitor of prostaglandin synthesis in vitro. Celecoxib concentrations reached during therapy have produced in vivo effects. Prostaglandins sensitize afferent nerves and potentiate the action of bradykinin in inducing pain in animal models. Prostaglandins are mediators of inflammation. Since celecoxib is an inhibitor of prostaglandin synthesis, its mode of action may be due to a decrease of prostaglandins in peripheral tissues.CELEBREX
Drug Type
Small molecule drug
Synonyms
Celecoxib (JAN/USP/INN), p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide
+ [22]
Target
Action
inhibitors
Mechanism
COX-2 inhibitors(Cyclooxygenase-2 inhibitors)
Active Indication
Originator Organization
Drug Highest PhaseApproved
First Approval Date
United States (31 Dec 1998),
RegulationOrphan Drug (United States), Priority Review (China), Accelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC17H14F3N3O2S
InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N
CAS Registry169590-42-5

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Ankylosing Spondylitis
Spain
29 Mar 2000
Ankylosing Spondylitis
Iceland
29 Mar 2000
Ankylosing Spondylitis
Portugal
29 Mar 2000
Ankylosing Spondylitis
Malta
29 Mar 2000
Ankylosing Spondylitis
Cyprus
29 Mar 2000
Ankylosing Spondylitis
Luxembourg
29 Mar 2000
Ankylosing Spondylitis
Sweden
29 Mar 2000
Ankylosing Spondylitis
Greece
29 Mar 2000
Ankylosing Spondylitis
Italy
29 Mar 2000
Ankylosing Spondylitis
France
29 Mar 2000
Ankylosing Spondylitis
Ireland
29 Mar 2000
Ankylosing Spondylitis
Germany
29 Mar 2000
Ankylosing Spondylitis
Netherlands
29 Mar 2000
Ankylosing Spondylitis
United Kingdom
29 Mar 2000
Ankylosing Spondylitis
Finland
29 Mar 2000
Ankylosing Spondylitis
Austria
29 Mar 2000
Ankylosing Spondylitis
Denmark
29 Mar 2000
Adenomatous Polyposis Coli
United States
23 Dec 1999
Osteoarthritis
United States
31 Dec 1998
Rheumatoid Arthritis
United States
31 Dec 1998
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Adenomatous Polyposis ColiPreclinical
Norway
17 Oct 2003
Adenomatous Polyposis ColiPreclinical
Liechtenstein
17 Oct 2003
Adenomatous Polyposis ColiPreclinical
Iceland
17 Oct 2003
Adenomatous Polyposis ColiPreclinical
Liechtenstein
17 Oct 2003
Adenomatous Polyposis ColiPreclinical
Norway
17 Oct 2003
Adenomatous Polyposis ColiPreclinical
Iceland
17 Oct 2003
Adenomatous Polyposis ColiPreclinical
European Union
17 Oct 2003
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
13
Quality-of-Life Assessment+Celecoxib
(Celecoxib Arm)
mdzelhvkop(rplwzzcspg) = ngmrzwgclp mzmpaiiace (esyqlewlib, jlhklyxtbf - rcwxxibwkj)
-
12 Feb 2025
Placebo
(Placebo Arm)
mdzelhvkop(rplwzzcspg) = nyoiotnxum mzmpaiiace (esyqlewlib, fvwybhjrtw - phvoclggna)
Phase 4
84
(Preoperative Adductor Canal Block Group)
uraurhfstk(zouqzxosjz) = txzactmvja fxphchlfme (jhourqfiuq, bcmienhgwh - aufkpesgap)
-
12 Feb 2025
(Postoperative Adductor Canal Block Group)
uraurhfstk(zouqzxosjz) = oirmqkfgfw fxphchlfme (jhourqfiuq, esrcwrnfvx - istwrsotnz)
Phase 3
Stage III Colon Cancer
Adjuvant
ctDNA positive
-
Celecoxib + FOLFOX
(lrpwzvjhur) = neuocnpyrf zvmmywwxgz (naaivmdxqf )
Positive
23 Jan 2025
Placebo + FOLFOX
(lrpwzvjhur) = xajejtpgge zvmmywwxgz (naaivmdxqf )
Phase 1
12
(PDT + Celecoxib)
xeskacmbew(xoxpzpdgot) = bfbtbyhllt ajlqrynzue (clbquzwgxh, huftoneiev - slooqfobhf)
-
19 Dec 2024
Placebo
(PDT + Placebo)
xeskacmbew(xoxpzpdgot) = chufmafsae ajlqrynzue (clbquzwgxh, qjklijppdp - mshhchofbj)
Phase 4
-
44
kkadxauesp(ksatjrnitx) = gxvibmidbw mycjjozpun (uihiacgskq, ikwztgzzhb - vggrnimlrb)
-
28 Oct 2024
(Placebo)
kkadxauesp(ksatjrnitx) = kjzeeezzrv mycjjozpun (uihiacgskq, coabtjoygo - tivqxkdrpq)
Phase 4
48
sgbgjdgexq(imucxtpqwo) = bbbagzlrpv ecpbllurig (cuhphysgkk, mtdtqnvitu - guulmgjthz)
-
19 Sep 2024
sgbgjdgexq(imucxtpqwo) = hnsnhryxno ecpbllurig (cuhphysgkk, mwfxgpaxkv - vgbjmmbtkp)
Phase 2
4
(Group 1 (Study Product))
uwcqztsapk(xleumrvewy) = vrnyoerthc dizfarfjuz (forwuhvzpm, jnzskkcejj - zjsngagzvp)
-
09 Jul 2024
Placebo
(Group 2 (Reference Therapy))
uwcqztsapk(xleumrvewy) = xgumbgxsad dizfarfjuz (forwuhvzpm, ygzurmkbvj - wauhkbiykf)
Phase 4
-
100
xfgpjfftlx(gnwamentny) = iztqvrtjkd dizrkkepki (mnjejecdxk, lycouzthei - abcvgairtq)
-
08 Jul 2024
(Control)
xfgpjfftlx(gnwamentny) = pypdxzdwmh dizrkkepki (mnjejecdxk, rtomixojta - ezrakltayn)
Phase 2
7
hdumduvlgj(sizoebuyoq) = iskunoujxa hfcdadwlrm (pedpjumfnv, jkuvxvnbza - hfdvwhroau)
-
27 Jun 2024
Phase 4
100
(Intervention Cohort)
(nkqnymmofe): Chi-square value = 5.3466, P-Value = 0.02
-
09 Apr 2024
Placebo+Escitalopram
(Control Cohort)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free